MMJ Recs

DECEMBER 17, 2023

The Texas Compassionate Use Program (TCUP) represents the Lone Star State’s cautious foray into the realm of medical marijuana. Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals.

Law 52

Law Dispensary Clinical Trials Programs 52

The Cannigma

MAY 19, 2021

Japanese authorities can prosecute citizens for violating its cannabis laws — even if they used it abroad. Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. The post Cannabis laws in Japan: Is weed legal? Shutterstock).

Law 137

Law Legalization Clinical Trials CBD 137

The Cannigma

OCTOBER 14, 2022

However, the laws don’t differentiate between soft drugs and hard drugs. San Marino medical marijuana program. The program does not include cannabis flower or home grow. The post Cannabis laws in San Marino appeared first on The Cannigma. This medication is provided at no cost to residents of the country.

Law 56

Law Clinical Trials Research and Development Recreational 56

Cannabis Law Report

MAY 19, 2022

This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.

Therapy 52

Therapy Treatment Clinical Trials Access 52

Cannabis Law Report

JUNE 2, 2021

Researchers studying the efficacy of marijuana treatments for veterans’ mental health now have access to $20 million in marijuana tax revenue to fund clinical trials. The Marijuana Regulatory Agency issued a request for proposals for the 2021 Veteran Marijuana Research Grant Program on Tuesday, June 1. Read more at.

Clinical Trials 105

Clinical Trials Marijuana Recreational Collective 105

Cannabis Law Report

MAY 6, 2021

EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS).… … Read More.

Clinical Trials 59

Clinical Trials Therapy Programs Medicine 59

MMJ Recs

MAY 9, 2024

There are multiple US states with an established state-approved medical marijuana program as well as states permitting the use of cannabinol (CBD) oil – a non-psychoactive component of cannabis – for medical purposes exclusively.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

JULY 9, 2021

The state of the law on psychedelic substances is in flux. Some of the most promising substances, and the law applicable to each, are outlined below: Psilocybin. As such, the use, sale, and possession of psilocybin in the United States is illegal under federal law. have also passed “Right to Try” laws.

Law 105

Law Therapy Clinical Trials Research and Development 105

SpeedWeed

JULY 6, 2021

Harvard Law School is planning to open the first US policy center focused on the legalization and regulation of psychedelics like psilocybin, MDMA, and LSD. . This new program is being funded by private investors, including Matt Wullenweg, developer of WordPress, and philanthropist Tim Ferriss. Professor of Law at Harvard Law School.

Policy 52

Policy Law Research and Development Therapy 52

Cannabis Law Report

AUGUST 7, 2021

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Cannabis Law Report

AUGUST 10, 2022

According to CAMH’s lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce “ sustained antidepressant effects” in individuals living with severe depression.

Clinical Trials 52

Clinical Trials Research and Development Therapy Microdosing 52

Canna Law Blog

NOVEMBER 10, 2020

Public Law 115-176 (“Right to Try”) is a federal law enacted in 2018 that creates a uniform system for terminal patients seeking access to investigational treatments. Right to Try was first introduced as state legislation, with similar laws in 41 states (the federal law does not contain preemption language).

Therapy 80

Therapy Clinical Trials Decriminalization Patients 80

Cannabis Law Report

MARCH 30, 2022

Senate Bill 253: The Cannabidiol and Marihuana Research Expansion Act provides the office of US Attorney General, rather than the US Drug Enforcement Administration, the discretion to license scientists to engage in clinical trials involving the use of cannabis by human subjects.

Legislation 95

Legislation Clinical Trials DEA Access 95

Cannabis Law Report

JULY 13, 2022

“Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”.

Therapy 52

Therapy Clinical Trials Microdosing Research and Development 52

Cannabis Law Report

DECEMBER 27, 2019

Virtual Clinical Trials transcend geographic, mobility and economic barriers. Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.

Clinical Trials 85

Clinical Trials Access Research and Development Supply Chain 85

Cannabis Law Report

OCTOBER 12, 2021

Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle™, a pooled COVID-19 testing program that is grounded in the Company’s EUA-authorized Linea™ COVID-19 Assay Kit. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.

Programs 52

Programs Clinical Trials Research and Development Therapy 52

Cannabis Law Report

DECEMBER 2, 2021

Recommendations and rulemaking relating to training and products were placed on an expedited timeline to ensure that facilitators will be trained, and products will be ready for the January 2, 2023, launch of the first state-sponsored psilocybin therapy program in the United States. Conducting a Psilocybin Administration Session (20 Hours).

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

AUGUST 3, 2021

Cybin was well funded before this financing, and this new funding now further extends the runway for our drug programs, discovery pipeline and IP portfolio, and provides additional flexibility to support potential M&A opportunities. Securities Act and applicable state securities laws. Securities Act or under any U.S. About Cybin.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

JUNE 19, 2022

Unlike novel chemical compounds that are synthetically produced in the pharmaceutical industry through drug development programs, psychedelic compounds have a long and established history. As we see more data emerge from clinical trials, we are likely to see patent applications covering stability, pharmacokinetic, and pharmacodynamic data.

Clinical Trials 52

Clinical Trials Microdosing Data Pharmaceutical 52

Cannabis Law Report

FEBRUARY 24, 2022

Canada’s Special Access Program (SAP) allows health care professionals to request drugs for patients with serious or life-threatening conditions where other available treatments fail to work (analogous to the Right to Try (RTT) program in the United States ). Timeline of Medicinal Legalization in Canada. Pursuant to subsection C.08.010(1)

Therapy 52

Therapy Access Clinical Trials Treatment 52

Cannabis Law Report

DECEMBER 9, 2021

The Company believes it has produced a sufficient supply of cGMP DMT to complete its planned Phase 1 and Phase 2 clinical trials. as medical consultants to the Company’s DMT stroke clinical research program. Simister have extensive backgrounds in stroke management as well as clinical care and stroke research.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

AUGUST 17, 2021

Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. Conference Call and Webcast Details. Marinus will host a conference call and webcast with slides at 4:30 p.m.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

AUGUST 14, 2021

The deal signed in March had sought to progress an over-the-counter medicine with the TGA using Emyria’s EMD-003 program and Cann’s Gelpell technology. Cann Group (CAN) and Emyria (EMD) mutually agree to drop a deal for the proposed registration of a Schedule 3 cannabidiol (CBD) product.

CBD 105

CBD Clinical Trials Programs Food 105

Canna Law Blog

NOVEMBER 27, 2021

In fact, Small Pharma has been conducting trials as reported by the BBC and expanded its clinical trial this past summer. regulators to launch a clinical program to study the use of DMT for the treatment of stroke-related dysfunction. Compass Pathways Releases Phase 2B Trial Results.

Therapy 89

Therapy Clinical Trials DEA Microdosing 89

Cannabis Law Report

AUGUST 2, 2021

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

Cannabis Law Report

OCTOBER 13, 2021

Filed in support of the Company’s CYB004 pre-clinical development program, the PCT filing serves to increase the Company’s library of drug delivery modalities directed to optimal delivery of psychedelics and further strengthens Cybin’s growing IP portfolio. Vigorous scientific research and clinical trials are needed.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

JUNE 7, 2021

Filament Health partnered with TrPR Psychedelic Research Program at UCSF to advance drug candidates through clinical trials. (CSE: NOVA). 0.080 -0.015 (-15.79%). View All Index Constituents. Corporate News, Deals & Listings. Press Release. BetterLife Pharma Inc. Press Release.

Research and Development 98

Research and Development Clinical Trials Extraction Retail 98

SpeedWeed

MARCH 13, 2021

However, Michigan law requires that the treasury department use that revenue to “provide $20 million annually to one or more clinical trials … researching the efficacy of marihuana in treating the medical conditions of United States armed services veterans and preventing veteran suicide.”. View original article.

Clinical Trials 52

Clinical Trials Conditions Programs Recreational 52

Cannabis Law Report

OCTOBER 2, 2021

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

SEPTEMBER 10, 2021

We’re thrilled to be working with a company that shares our vision and is committed to making Europe a leader in the field by providing world-class clinical expertise tailored to the nuances of psychedelic therapy.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

JUNE 11, 2021

The transition of the Company’s leadership team will enable the Company to pursue aggressively its clinical development programs and development of its companion innovative digital technologies. This chief executive officer transition is a natural progression for MindMed as the Company heads into later stage clinical trials.

Clinical Trials 95

Clinical Trials Research and Development Pharmaceutical Medicine 95

Cannabis Law Report

JUNE 23, 2021

. “Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic drugs, therapies, and enabling technologies to treat Addiction, and delivering psychedelic treatments for Addiction in our clinics,” said Awakn CEO, Anthony Tennyson. David Nutt), starts in Q4 2021.

Clinical Trials 110

Clinical Trials Therapy Research and Development Treatment 110

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC is a Public Benefit Corporation, with a dual mandate to generate shareholder value and public benefit.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. Exploring CBD for Medical Use As interest in CBD grows, researchers are continuously exploring its potential applications in the medical field.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

JANUARY 12, 2022

“We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. ” Gb Sciences’ intellectual property portfolio includes five U.S. 31, 2021.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

NORML

JANUARY 4, 2019

Steve Cohen (D-TN) and Don Young (R-AK) re-introduced the Compassionate Access, Research Expansion and Respect States (CARERS) Act, which protects those engaged in state-lawful medical marijuana programs from federal prosecution. Click here to email your member of Congress and urge them to join the Cannabis Caucus. MA resident?

Legislation 126

Legislation Clinical Trials Research and Development Access 126